Santhera Pharmaceuticals’ Agamree (vamorolone) has been accepted by the Scottish Medicines Consortium (SMC) to treat Duchenne ...

Idorsia transfers rights to royalties and milestones for AGAMREE (vamorolone) to R-Bridge Healthcare Fund through a monetization agreement In 2020, Idorsia’s license, collaborative development ...

Santhera Pharmaceuticals will launch its new drug for Duchenne muscular dystrophy in the UK within the next few weeks, after ...

This follows confirmation that no appeals were received against the Final Draft Guidance (FDG) recommendation announced on December 10, 2024. Following this, Santhera has already started launch ...

Recent acquisition of AGAMREE from SANTHERA in 07/2023 strengthens Catalyst's product portfolio. I discuss its recent favorable settlement as announced in its 01/08/2025 release (the "Release").

(RTTNews) - Santhera Pharmaceuticals said that it received positive recommendation from the Scottish Medicines Consortium for use of AGAMREE (Vamorolone) within NHS Scotland for the treatment of ...

Pratteln, Switzerland, January 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that Idorsia Pharmaceuticals has entered into a royalty monetization agreement with the R-Bridge Healthcare ...

Following this, Santhera has already started launch preparations for AGAMREE in the UK and expect first sales in this quarter. AGAMREE is the first and only medicinal product for DMD to have ...